Last reviewed · How we verify
LSC2
At a glance
| Generic name | LSC2 |
|---|---|
| Also known as | Suspension of ABCB5-positive limbal stem cells in pre-filled syringe |
| Sponsor | RHEACELL GmbH & Co. KG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LSC2 CI brief — competitive landscape report
- LSC2 updates RSS · CI watch RSS
- RHEACELL GmbH & Co. KG portfolio CI